This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Thalidomide in Treating Patients With Recurrent or Persistent Cancer of the Uterus

This study has been completed.
Information provided by (Responsible Party):
National Cancer Institute (NCI) Identifier:
First received: October 11, 2001
Last updated: March 13, 2015
Last verified: December 2012
Phase II trial to study the effectiveness of thalidomide in treating patients who have recurrent or persistent cancer of the uterus. Thalidomide may stop the growth of cancer by stopping blood flow to the tumor.

Condition Intervention Phase
Recurrent Uterine Corpus Sarcoma Uterine Corpus Leiomyosarcoma Drug: Thalidomide Other: Laboratory Biomarker Analysis Phase 2

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase II Evaluation of Thalidomide (NSC #66847) in the Treatment of Recurrent or Persistent Leiomyosarcoma of the Uterus

Resource links provided by NLM:

Further study details as provided by National Cancer Institute (NCI):

Primary Outcome Measures:
  • Progression-free survival [ Time Frame: 6 months ]
  • Frequency and severity of adverse effects as assessed by CTC [ Time Frame: Up to 7 years ]

Secondary Outcome Measures:
  • Duration of progression-free survival [ Time Frame: Up to 7 years ]
  • Duration of overall survival [ Time Frame: Up to 7 years ]
  • Frequency of clinical response (partial and complete response) [ Time Frame: Up to 7 years ]

Enrollment: 60
Study Start Date: September 2001
Study Completion Date: July 2008
Primary Completion Date: April 2003 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Treatment (thalidomide)
Patients receive oral thalidomide once daily on days 1-28. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
Drug: Thalidomide
Given PO
Other Name: THAL
Other: Laboratory Biomarker Analysis
Correlative studies

Detailed Description:


I. Determine the antitumor cytostatic activity of thalidomide, as measured by the probability of progression-free survival (PFS) for at least 6 months, in patients with recurrent or persistent uterine leiomyosarcoma.

II. Determine the nature and degree of the toxicity of this drug in these patients.

III. Determine the partial and complete response rates in patients treated with this drug.

IV. Determine the duration of PFS and overall survival of patients treated with this drug.

V. Determine the effect of this drug on initial performance status in these patients.

VI. Determine the effects of this drug at 4 weeks on endogenous angiogenesis factors (vascular endothelial growth factor and basic fibroblast growth factor) in plasma and urine of these patients.

VII. Assess the association of endogenous angiogenesis factors with clinical outcome (PFS) in patients treated with this drug.

OUTLINE: This is a multicenter study.

Patients receive oral thalidomide once daily on days 1-28. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.

Patients are followed every 3 months for 2 years, every 6 months for 3 years, and then annually thereafter.


Ages Eligible for Study:   Child, Adult, Senior
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Histologically confirmed primary uterine leiomyosarcoma (LMS) that is refractory to curative therapy or established treatments

    • Recurrent or persistent disease
  • At least 1 unidimensionally measurable target lesion

    • At least 20 mm by conventional techniques, including palpation, plain x-ray, CT scan, or MRI OR at least 10 mm by spiral CT scan
    • Tumors within a previously irradiated field are considered non-target lesions
  • No smooth muscle tumor of uncertain malignant potential, including metastatic or recurrent disease from such a tumor
  • Must have received 1 prior initial chemotherapy regimen (including high-dose, consolidation, or extended therapy after surgical or nonsurgical assessment) for uterine LMS
  • Ineligible for a higher priority Gynecological Oncology Group (GOG) protocol (if one exists), including any active phase III protocol for the same patient population
  • No documented brain metastases since diagnosis of cancer

    • Patients with stable CNS deficits are allowed provided there are no brain metastases, as confirmed by CT scan or MRI
  • Performance status - GOG 0-2 if received 1 prior therapy regimen
  • Performance status - GOG 0-1 if received 2 prior therapy regimens
  • Absolute neutrophil count at least 1,500/mm^3
  • Platelet count at least 100,000/mm^3
  • Bilirubin no greater than 1.5 times upper limit of normal (ULN)
  • SGOT no greater than 2.5 times ULN
  • Alkaline phosphatase no greater than 2.5 times ULN
  • Creatinine no greater than 1.5 times ULN
  • Creatinine clearance greater than 60 mL/min
  • No documented seizure disorders since diagnosis of cancer
  • Patients with a history of seizure disorders are allowed provided that the seizures have been stable (i.e., no seizure within the past 12 months)while on an appropriately monitored treatment regimen
  • No active infection requiring antibiotics
  • No greater than grade 1 sensory or motor neuropathy
  • No other prior invasive malignancy within the past 5 years except nonmelanoma skin cancer
  • Not pregnant
  • Negative pregnancy test
  • Fertile patients must use at least 1 highly active method and 1 additional effective method of contraception for at least 4 weeks before, during, and for at least 4 weeks after study participation
  • No prior thalidomide
  • At least 3 weeks since prior immunologic agents for uterine LMS
  • At least 3 weeks since other prior chemotherapy for uterine LMS and recovered
  • No more than 1 prior cytotoxic chemotherapy regimen for recurrent or persistent uterine LMS
  • No prior non-cytotoxic chemotherapy for recurrent or persistent uterine LMS
  • At least 1 week since prior hormonal therapy for uterine LMS
  • Concurrent hormone replacement therapy allowed
  • At least 3 weeks since prior radiotherapy for uterine LMS and recovered
  • No prior radiotherapy to more than 25% of bone marrow
  • Recovered from recent prior surgery
  • No prior anticancer therapy that would preclude study therapy
  • At least 3 weeks since other prior therapy for uterine LMS
  • No concurrent bisphosphonates (e.g., zoledronate)
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00025220

United States, Pennsylvania
Gynecologic Oncology Group
Philadelphia, Pennsylvania, United States, 19103
Sponsors and Collaborators
National Cancer Institute (NCI)
Principal Investigator: D. McMeekin Gynecologic Oncology Group
  More Information

Responsible Party: National Cancer Institute (NCI) Identifier: NCT00025220     History of Changes
Other Study ID Numbers: NCI-2012-02415
NCI-2012-02415 ( Registry Identifier: CTRP (Clinical Trial Reporting Program) )
GOG-0231-B ( Other Identifier: Gynecologic Oncology Group )
GOG-0231B ( Other Identifier: CTEP )
U10CA027469 ( U.S. NIH Grant/Contract )
Study First Received: October 11, 2001
Last Updated: March 13, 2015

Additional relevant MeSH terms:
Neoplasms, Muscle Tissue
Neoplasms, Connective and Soft Tissue
Neoplasms by Histologic Type
Immunosuppressive Agents
Immunologic Factors
Physiological Effects of Drugs
Leprostatic Agents
Anti-Bacterial Agents
Anti-Infective Agents
Angiogenesis Inhibitors
Angiogenesis Modulating Agents
Growth Substances
Growth Inhibitors
Antineoplastic Agents processed this record on August 18, 2017